The #Nimbi team was proud to participate in Bio-Ball 2024 to support Special Olympics athletes and encourage inclusion and community! Thanks to our team’s incredible fundraising effort, the Nimbus/Haverhill Team won the opportunity to compete on the parquet floor at TD Garden in November! Looking forward to the rematch! #bioball #ChooseToInclude
Nimbus Therapeutics
Biotechnology Research
Cambridge, Massachusetts 13,980 followers
Applying deep computational chemistry expertise to create novel small molecule therapeutics.
About us
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
- Website
-
http://www.nimbustx.com/
External link for Nimbus Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Specialties
- computational chemistry, biochemistry, small molecule therapeutics, oncology, immunology, metabolism, and drug development
Locations
-
Primary
Get directions
130 Prospect St
Ste 301
Cambridge, Massachusetts 02139, US
Employees at Nimbus Therapeutics
Updates
-
At the American Society of Clinical Oncology (ASCO) Annual Meeting, our Chief Executive Officer Jeb Keiper met with Brad Loncar, Founder of BiotechTV, to talk about our investigational HPK1 inhibitor in the treatment of advanced solid tumors. See the video below. #ASCO24
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒: Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24. He describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has helped it discover and develop this asset. Full video: https://lnkd.in/g5XH2fAg BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Nimbus Therapeutics reposted this
This weekend a bunch of biotech colleagues turned out for the Boston Pride For The People parade! Way to go Nimbus Therapeutics ROME Therapeutics Obsidian Therapeutics marchers!!
-
-
Wishing Boston Pride For The People a wonderful #PrideMonth celebration today! We join you in recognizing the rich diversity, culture, and intersectionality of the LGBTQ+ community. #BP4TP
-
-
The Nimbus Green Team aims to foster #sustainability practices within and outside the workplace. Yesterday we had the opportunity to volunteer with Boston Harbor Now and the Friends of Boston Harborwalk – organizations that have been instrumental in maintaining the Harborwalk across 43 miles of Boston's waterfront. Together we can create meaningful and sustainable change in Boston communities.
-
-
It’s almost time to rain some 3s for a wonderful cause. The #Nimbi team is excited to participate in the annual Bio-Ball tournament! There is still time to participate by donating to support Special Olympics athletes. https://lnkd.in/eKpV9RQR #ChooseToInclude
No Chemistry S2 Episode 2 This week we're giving a rundown on our next set of Bio-Ball teams: Seres Therapeutics (Matthew Henn)/Cape Ann, Alcyone Therapeutics Inc. (Greg Smith)/Cardinal Cushing, Nimbus Therapeutics (Jeb Keiper)/Haverhill, and Tome Biosciences (Rahul Kakkar)/Dorchester. 🏀Some new teams and some veterans - who will be the final 6 at TD Garden? Toss Up: New t-shirt color, who we would want on our team in a street fight, and the better point guard. Stay tuned for episode 3 coming to you next week! Special Olympics Massachusetts Gregg Beloff Steve Huftalen #bioball 2seventy bio Alnylam Pharmaceuticals Apellis Pharmaceuticals Blueprint Medicines BlueRock Therapeutics Flagship Pioneering Kelonia Therapeutics Nuvalent, Inc. Sage Therapeutics Sanofi Third Rock Ventures Commonwealth Financial Group
-
A great piece by PharmaVoice that highlights our #drugdiscovery and development approach, where each program is an independent subsidiary, and dives into our #HPK1 clinical trial in solid tumors.
With the billion-dollar-plus deals under its belt with Gilead Sciences and Takeda, Nimbus Therapeutics CEO Jeb Keiper explains where the company is going next. #biotech #oncology https://lnkd.in/eJyHeNdK
-
We're honored to be part of last night’s CelebrAsians Gala hosted by Asian Women for Health. We heard inspiring stories from Community Health Workers making a difference by bridging the gap between communities and essential healthcare. What a way to close out #AAPIHeritageMonth with a message of hope and equity!
-
-
On June 3rd Erin Cowhig, Chief People Officer, will join a panel of industry experts and thought leaders to address the most pressing topics facing HR Leaders and their organizations. The event is part of the Life Sciences Human Resources Leaders series hosted by The Bowdoin Group and Marsh McLennan Agency. #MMALifeSciencesPractice
-
-
The #Nimbi team is looking forward to attending the American Society of Clinical Oncology (ASCO) Annual Meeting next week. Marcus Noel, M.D., will present new positive monotherapy data from a Phase 1/2 trial evaluating our investigational HPK1 inhibitor in the treatment of advanced solid tumors. https://lnkd.in/e7_RE_7A #ASCO24
-